IGI
LIVE

Serial Number

98384819

Owner

Glenmark Pharmaceuticals Limited

Attorney

Maxim A. Voltchenko

Filing Date

Jan 31, 2024

Add to watchlist:

No watchlists yet
View on USPTO

IGI Trademark

Serial Number: 98384819

IGI is a trademark filed by Glenmark Pharmaceuticals Limited on January 31, 2024. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Glenmark Pharmaceuticals Limited (11 trademarks)

2/B Mahalaxmi Chamber 22
Mumbai , IN

Entity Type: 03

Trademark Details

Filing Date

January 31, 2024

Registration Date

Not Registered

Published for Opposition

December 10, 2024

Goods & Services

Skin soaps; shampoos; sunscreen for cosmetic use; perfumery; essential oils; body powder; cosmetics; anti-aging creams; hair lotion; skin creams; skin moisturizing gels; non-medicated soaps for face; moisturizing body lotions; non-medicated mouthwashes

Spirometer; inhalers for therapeutic use, sold empty; chambers for inhalers; nebulizers for medical purposes; diagnostic apparatus for medical purposes, namely, medical diagnostic apparatus for testing DNA and RNA samples

Scientific research for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; scientific and technological services, namely, scientific research and analysis in the field of chemicals, pharmaceutical preparations, dietetic preparations, demo-cosmetic preparations, and biotechnology; design and testing for new product development; medical research; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services; scientific research services for medical purposes, namely, bacteriological research services; biomedical research services; laboratory research services in the field of cancer treatment, oncology, immunology and pain management; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of pharmacology; medical research services conducted in a laboratory; scientific and technological services, namely, scientific research and analysis, in the fields of medicine, health, fitness, exercise and wellness; consulting services in the field of pharmaceutical research and development, namely, consultation and collaboration with industry and academic professionals for the identification, research and development of new manufacturing technologies in the field of pharmaceuticals

Providing information in the field of medicine and health; medical services; medical assistance services; hygiene care for human beings being health care services; medical clinic services; providing medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases

Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 4, 2026 EXRA
SOU EXTENSION 2 GRANTED
Feb 3, 2026 EX2G
SOU EXTENSION 2 FILED
Feb 3, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 3, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Aug 4, 2025 EX1G
SOU EXTENSION 1 FILED
Aug 3, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 3, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 19, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 19, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 19, 2025 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 4, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 4, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 15, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 14, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 14, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 26, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 26, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 26, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 26, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 1, 2024 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 1, 2024 NWOS
NEW APPLICATION ENTERED
Jan 31, 2024 NWAP